0001171000-15-000106.txt : 20151124 0001171000-15-000106.hdr.sgml : 20151124 20151124151257 ACCESSION NUMBER: 0001171000-15-000106 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151123 FILED AS OF DATE: 20151124 DATE AS OF CHANGE: 20151124 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nexvet Biopharma plc CENTRAL INDEX KEY: 0001618561 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 BUSINESS PHONE: 353 1 215 8100 MAIL ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 FORMER COMPANY: FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd DATE OF NAME CHANGE: 20140903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Heffernan Mark CENTRAL INDEX KEY: 0001632439 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36828 FILM NUMBER: 151252475 MAIL ADDRESS: STREET 1: C/O NEXVET BIOPHARMA PLC STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK STATE: L2 ZIP: 00000 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2015-11-23 0001618561 Nexvet Biopharma plc NVET 0001632439 Heffernan Mark C/O NEXVET BIOPHARMA PLC UNIT 5, SRAGH TECHNOLOGY PARK,RAHAN ROAD TULLAMORE , CO. OFFALY L2 R35 FR98 IRELAND 0 1 0 0 Chief Executive Officer Ordinary Shares 2015-11-23 4 M 0 7250 .125 A 19334 D Ordinary Shares 243587 I By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C> Option to Purchase Shares .125 2015-11-23 4 M 0 7250 0 D 2020-11-05 Ordinary Shares 7250 9666 I By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C> The reporting person and his spouse share voting and dispositive power with respect to these reported securities. 7,250 options to purchase shares vested and became exercisable on 11/19/15 after the Issuer's board of directors determined that there had been successful completion of an efficacy trial for an Issuer product. A further 4,833 options to purchase shares will vest and become exercisable on each of 7/1/16 and 7/1/17. /s/ Mark Heffernan by Geraldine T. Farrell, Attorney-in-Fact 2015-11-23